APhA Annual Meeting and Exposition - American Pharmacists Association Annual Meeting and Exposition

Public perceptions on naloxone may differ by community.

At the American Pharmacists Association 2017 meeting, an inspiring and practical session titled “Leading by Example” showed how pharmacists can leverage their value to establish health care team partnerships (eg, with health systems and physician practices) and implement programs to win pharmacy “champions,” improve patient outcomes, and reduce health care costs.

Pharmacists play an important role in helping to deal with clinical inertia.

There are several new options coming down the pipeline for patients with type 2 diabetes.

Continuing education remains an important part of a pharmacist's life, particularly those dealing with an ever-increasing population of patients with diabetes.

There are several new treatments in the pipeline that hold promise for patients with type 2 diabetes.

Sessions focuses on new diabetes treatment options.

Two new fixed-dose basal/GLP-1 receptor-agonist agents, Soliqua 100/33 (Sanofi) and Xultophy 100/3.6 (Novo Nordisk), were approved by the FDA in November 2016.

In this clip, Jeffrey Fudin, PharmD, who spoke at APHA 2017 on opioid tapering, discusses options pharmacists should consider when tapering patients.

In this clip, Jeffrey Fudin, PharmD, discusses available options in abuse-deterrent formulations of opioids.

APhA is about to kick off and we'll be there all weekend covering it live!